ReviewInternal and emergency medicine2026
Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis.
Review in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus and obesity constitute major global public health concerns, with their incidence continuing to rise worldwide. These metabolic conditions are closely interrelated and commonly coexist, exerting a synergistic impact on cardiovascular morbidity and mortality. The interplay between diabetes, obesity, and atherosclerotic cardiovascular disease has become a focal point of research, as elucidating their pathophysiological underpinnings and prognostic implications is crucial for establishing effective prevention and treatment approaches. Beyond their established effects on weight reduction and glycemic regulation, GLP-1RAs and GIP/GLP-1RAs, emerging pharmacological classes targeting obesity and diabetes, have demonstrated significant impact on atherosclerotic processes and cardiovascular outcomes Keywords: atherosclerosis, obesity, type 2 diabetes mellitus, GLP1-RAs, GIP/GLP1-RAs.
Indexed as
Identifiers
42313337What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.